fidaxomicin 和其主要代谢产物 OP-1118 对艰难梭菌的抗生素后效应。
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
机构信息
Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Rd., Suite C, San Diego, CA 92121, USA.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
Abstract
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).
摘要
非达霉素（FDX）是一种窄谱抗生素，最近的研究表明，它在治疗艰难梭菌感染方面优于万古霉素，能提供持续的临床应答。本研究检测了 FDX 及其主要代谢产物 OP-1118 的抗生素后效应（PAE）。结果显示，FDX 的 PAE 较长（ATCC 株为 10 h，临床分离株为 5.5 h），而 OP-1118 的 PAE 长于标准对照药万古霉素（分别为 3 h 和 0-1.5 h）。
相似文献
1
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
2
Fidaxomicin inhibits spore production in Clostridium difficile.
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453.
3
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Antimicrob Agents Chemother. 2013 Jan;57(1):664-7. doi: 10.1128/AAC.01611-12. Epub 2012 Nov 12.
4
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
J Med Microbiol. 2011 Aug;60(Pt 8):1213-1217. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24.
5
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
Antimicrob Agents Chemother. 2014 May;58(5):2934-7. doi: 10.1128/AAC.02572-13. Epub 2014 Feb 18.
6
Antimicrobial activities of fidaxomicin.
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S143-8. doi: 10.1093/cid/cis339.
7
Fidaxomicin: in Clostridium difficile infection.
Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000.
8
Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.
Antimicrob Agents Chemother. 2010 Jun;54(6):2674-6. doi: 10.1128/AAC.01842-09. Epub 2010 Mar 22.
9
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
J Antimicrob Chemother. 2018 Jan 1;73(1):102-108. doi: 10.1093/jac/dkx353.
10
and Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01170-20.
引用本文的文献
1
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
BioDrugs. 2023 Nov;37(6):757-773. doi: 10.1007/s40259-023-00617-2. Epub 2023 Jul 26.
2
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.
J Antimicrob Chemother. 2022 Dec 23;78(1):21-30. doi: 10.1093/jac/dkac404.
3
Fidaxomicin for the Treatment of Infection in Adult Patients: An Update on Results from Randomized Controlled Trials.
Antibiotics (Basel). 2022 Oct 6;11(10):1365. doi: 10.3390/antibiotics11101365.
4
Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.
Infect Dis Ther. 2023 Jan;12(1):95-107. doi: 10.1007/s40121-022-00665-1. Epub 2022 Jul 19.
5
Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection.
Cureus. 2021 Jul 22;13(7):e16559. doi: 10.7759/cureus.16559. eCollection 2021 Jul.
6
Fidaxomicin for the treatment of in children.
Future Microbiol. 2020 Jul;15(11):967-979. doi: 10.2217/fmb-2020-0104. Epub 2020 Jul 27.
7
Scientific validation of the antimicrobial and antiproliferative potential of Berberis aristata DC root bark, its phytoconstituents and their biosafety.
AMB Express. 2019 Sep 11;9(1):143. doi: 10.1186/s13568-019-0868-4.
8
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778.
9
Management of Primary and Recurrent Infection: An Update.
Antibiotics (Basel). 2018 Jun 30;7(3):54. doi: 10.3390/antibiotics7030054.
10
Antibiotic Treatments for Infection Are Associated with Distinct Bacterial and Fungal Community Structures.
mSphere. 2018 Jan 10;3(1). doi: 10.1128/mSphere.00572-17. eCollection 2018 Jan-Feb.
本文引用的文献
1
Fidaxomicin versus vancomycin for Clostridium difficile infection.
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
2
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19.
3
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Expert Opin Pharmacother. 2010 Jun;11(9):1569-78. doi: 10.1517/14656566.2010.485614.
4
Clostridium difficile infection: new developments in epidemiology and pathogenesis.
Nat Rev Microbiol. 2009 Jul;7(7):526-36. doi: 10.1038/nrmicro2164.
5
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
Antimicrob Agents Chemother. 2009 Jan;53(1):261-3. doi: 10.1128/AAC.01443-07. Epub 2008 Oct 27.
6
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Antimicrob Agents Chemother. 2008 Nov;52(11):4163-5. doi: 10.1128/AAC.00476-08. Epub 2008 Aug 25.
7
Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.
Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5. doi: 10.1128/AAC.01045-07. Epub 2008 Feb 11.
8
Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.
Chemotherapy. 2007;53(4):267-74. doi: 10.1159/000104471. Epub 2007 Jun 25.
9
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9. doi: 10.1128/AAC.01623-06. Epub 2007 May 21.
10
Alternative treatments for Clostridium difficile disease: what really works?
J Med Microbiol. 2005 Feb;54(Pt 2):101-111. doi: 10.1099/jmm.0.45753-0.
Zotero 插件